An Essential Parameters of Voclosporin Include Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity and Enhancing Healthcare Team Outcomes

Voclosporin, a novel immunosuppressive medication, is approved regarding treatment as well as management of lupus nephritis (LN) within the class of calcineurin inhibitors (CNIs). LN is a common characterization of systemic lupus erythematosus (SLE), an autoimmune disease influencing various organs. Approximately 40% of SLE patients may generate LN. The primary goal of LN treatment is to maintain kidney function, decrease mortality, and promote the patient's quality of life while minimizing treatment-related adverse events. A timely response to therapy, as specified by a reduction in proteinuria, may predict long-term outcomes along with the risk of SLE flares, end-stage kidney disease as well as mortality. In the United States, voclosporin attained FDA approval in 2021 regarding treatment of active LN in adults, combined along with background immunosuppressive therapy. This CME activity explains about the indications, actions, and contraindications for voclosporin. It also specifies the mechanism of action, adverse event profile, and key factors like dosing, pharmacokinetics, contraindications, and monitoring that are essential for healthcare team members involved regarding treatment of patients along with lupus nephritis using voclosporin.